ESPE Abstracts (2015) 84 P-1-9


Founder Effect and the Clinical and Molecular Characteristics in a Cohort of Classical and Non-Classical Congenital Lipoid Adrenal Hyperplasia Due To StAR Mutations

Abdulsalam Abu-Libdeha, Ariella Weinberg Shokrunb, Ephrat Levy-Lahadb, Osnat Admonic, Yardena Tenenbaum-Rakoverd & David Zangena


aHadassah Hebrew University Medical Center, Jerusalem, Israel; bShaare Zedek Medical Center, Jerusalem, Israel; cHa’Emek Medical Center, Afula, Israel; dRappaport Faculty of Medicine, Technion, Haifa, Israel

Background: Classical and non-classical congenital lipoid adrenal hyperplasia (CLAH) are extremely rare condition caused by mutations in StAR. The degree of enzyme activity impairment determines the clinical phenotypes.

Objective and hypotheses: To identify the genetic cause of primary adrenal insufficiency in a cohort of patients from 13 unrelated families with classical and non-classical CLAH, to correlate genotype to phenotype and to identify a possible founder effect of these mutations.

Results: All (n=15) affected individuals with classical CLAH in Israel and the Palestinian territories had the same N-terminal c.201_202delCT mutation due to a founder effect and presented neonatally with severe Addissonian crisis and XY-DSD (in cases of XY karyotype) responding well to full replacement therapy. Three patients with non-classical CLAH had the G221S mutation (novel in the homozygous state), again with a founder effect. These patients presented during early childhood with addisonian crisis during a severe infection requiring just glucocorticoid replacement therapy. Characterization of the pubertal development in XX and XY patients of this cohort is underway.

Conclusion: Classical and non-classical CLAH due to StAR mutations are extremely rare but are significantly more common in the Palestinian population, given the founder effect of the two mutations characterized here. The different clinical phenotype of patients with classical and non-classical reflects the degree of StAR protein dysfunction caused by these mutations. To our knowledge, this is one of the largest cohorts studying the clinical and molecular characteristics of CLAH patients. The actual prevalence of mutations in the StAR gene in the general Palestinian population remains to be determined.

Article tools

My recent searches

No recent searches.

My recently viewed abstracts

No recent abstracts.